Navigation Links
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.

Dr. John S. Kovach, President and CEO of Lixte, said "LB-1.2 exerts anti-cancer activity directly on the cancer cell and, more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. Temozolomide, the standard drug for the treatment of patients with GBM, by itself caused regression but with recurrence of all tumors."

Dr. Kovach added "that, since LB-1.2 has a biochemical action similar to an older drug used for anticancer treatment for many years in China, we are cautiously optimistic that LB-1.2 will be well tolerated by cancer patients and hopefully, will potentially be as effective as it is in animal models of human cancer. We believe that adding LB-1.2 may be a general method for improving the effectiveness of several standard anticancer drugs not only against tumors of the brain and neural tissue but also against other cancers sensitive to drugs that work by damaging DNA. Safety, of course, must be demonstrated first in animal studies and subsequently in Phase I clinical trials before evaluation of therapeutic effectiveness can be assessed against different cancer types in patients."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS ( is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included on Form 10-QSB for the quarter ending March 31, 2009.

Please see our Website:

    For Investor Information, please contact:
    Jane Trigg
    631 830 7090

SOURCE Lixte Biotechnology Holdings
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
8. Yongye Biotechnology International Receives License to Manufacture Products
9. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
10. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
(Date:10/9/2015)... San Francisco, CA (PRWEB) , ... October 09, 2015 , ... ... with a study that aims to better understand the relationship between weight management and ... more frequently and more accurately from participants using an iPhone app. , The uBiome ...
(Date:10/8/2015)... 2015   Intrexon Corporation (NYSE: XON ... appointment of Joseph L. Vaillancourt as Senior ... Nimrodi who continues in his role as Head ... to generate sustainable, biologically based solutions to environmental problems. ... held a variety of key roles including, Vice President ...
(Date:10/8/2015)... N.J. , Oct. 8, 2015  Genetic testing ... may aid the identification of more couples at risk ... a study presented today at the 2015 American Society ... October 10 in Baltimore, Maryland . ... Quest Diagnostics (NYSE: DGX ) are presenting at ...
(Date:10/8/2015)... WAYNE, Pa. , Oct. 8, 2015 ... firm, has announced the call for applications for the ... , majoring in a life sciences related field of ... In addition, the selected Clarkston Scholar will receive exposure ... Consulting and participation in Pennsylvania Bio events over the ...
Breaking Biology Technology:
... ... product immediately, NATICK, Mass., April 14 Boston Scientific,Corporation ... Labor,and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular,lead ... failure. The Company also received reimbursement approval for,the lead from ...
... SGP ) is scheduled to announce its sales and ... 23, 2008., At 8 a.m. (EDT) on that ... for the 2008 first quarter and provide an update ... Fred Hassan,Schering-Plough,s chairman and CEO, and other members of ...
... For 88 percent of,companies, front-line and mid-level leaders ... variety of development skills but focus,strongly on techniques ... only half of executive-level sales leaders attend the ... and,training, according to a member-driven research study conducted ...
Cached Biology Technology:
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... Sept. 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... site, Touch of Modern, will feature the Wocket® smart ... th . Touch Of Modern ... designer lifestyle products to its 7.2 million members. Customers ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... -- A team of scientists led by Washington University in ... corn, a crop vital to U.S. agriculture. The researchers have ... that should accelerate efforts to develop better crop varieties to ... , Corn, also known as maize, underlies myriads of ...
... past year, various reports from the United Nations Intergovernmental Panel ... uncertain terms that in order to achieve a stable climate ... increase in CO2 emissions in the coming decades must be ... the IPCC, the maxi-mum amount of CO2 emissions that can ...
... do nearly 1 million people taking cholesterol-lowering statins often ... rare case when a diabetic takes medication for intestinal ... basis for the purported health effects of green tea? ... clinical explanation for these and other physiological mysteries. The ...
Cached Biology News:
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Synaptotagmin, phosphoSer309...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: